{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T22:00:08Z","timestamp":1793916008732,"version":"4.8.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:00:00Z","timestamp":1779148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T00:00:00Z","timestamp":1779494400000},"content-version":"vor","delay-in-days":4,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002957","name":"Technische Universit\u00e4t Dresden","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002957","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Chimeric antigen receptor (CAR)-engineered natural killer (NK) cells have shown potent efficacy against hematologic malignancies. In contrast, solid tumors remain difficult to treat due to heterogeneous antigen expression and an immunosuppressive tumor microenvironment that fosters immune evasion and is driven to a large part by checkpoint-mediated inhibition.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>To overcome these barriers, we engineered novel dual CAR-NK cells targeting the immune checkpoint PD-L1 and the tumor-associated antigen ErbB2 (HER2). The clinically applicable NK-92 cell line was lentivirally transduced with PD-L1.CAR and ErbB2.CAR constructs. Antitumor activity was assessed across diverse solid tumor models using a comprehensive panel of in vitro and in vivo assays.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Dual CAR-NK cells exhibited potent and selective cytotoxicity against breast, pancreatic, gastric, and lung cancer cell lines expressing either one or both targets. Comparable efficacy was observed in 3D spheroid cultures and against patient-derived primary ovarian cancer cells. Notably, dual CAR-NK cells retained strong cytotoxicity when one antigen was absent or blocked, modeling immune escape through antigen loss - a feature absent in single CAR-NK cells. Mechanistically, each CAR independently activated the MEK\/ERK pathway in an antigen-dependent manner, while dual CAR stimulation potentiated the signaling response in a cooperative manner. Furthermore, IFN-\u03b3 produced by NK cells upon encounter of resistant cancer cells was sufficient to induce PD-L1 upregulation, thereby enhancing the potency of the dual CAR system. In a PD-L1\/ErbB2 double-positive breast cancer xenograft model, dual CAR-NK cells consistently outperformed single-target controls.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Dual targeting of PD-L1 and ErbB2 enhances CAR-NK cell efficacy against refractory solid tumors by providing resilience to antigen heterogeneity and amplifying antitumor signaling through cooperative activation. This approach represents a promising and adaptable platform for clinical translation in solid tumor immunotherapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13046-026-03722-6","type":"journal-article","created":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T14:35:09Z","timestamp":1779201309000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Dual CAR-NK cells targeting PD-L1 and ErbB2 (HER2) exhibit cooperative CAR signaling and counteract solid tumor heterogeneity"],"prefix":"10.1186","volume":"45","author":[{"given":"Kristin","family":"Freudenberg-Jahn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Idan","family":"Ben-Horin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nivedha","family":"Murali Shankar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Schuldt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Ortiz-Montero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liliana R.","family":"Loureiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wiebke","family":"Rackwitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corinna","family":"Opitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lydia","family":"Krutz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Breither","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pranav","family":"Oberoi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aline","family":"H\u00e4cker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"J\u00e4ger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan Dominik","family":"Kuhlmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pauline","family":"Wimberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan R.","family":"K\u00fcnzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina","family":"H\u00f6lig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja","family":"Feldmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Bachmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Winfried S.","family":"Wels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Torsten","family":"Tonn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3175-2438","authenticated-orcid":false,"given":"Jiri","family":"Eitler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,19]]},"reference":[{"key":"3722_CR1","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1126\/science.aar6711","volume":"359","author":"CH June","year":"2018","unstructured":"June CH, O\u2019Connor RS, Kawalekar OU, Ghassemi S, Milone MC. CAR T cell immunotherapy for human cancer. Science. 2018;359:1361\u20135.","journal-title":"Science"},{"key":"3722_CR2","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1126\/science.aar4060","volume":"359","author":"A Ribas","year":"2018","unstructured":"Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science. 2018;359:1350\u20135.","journal-title":"Science"},{"key":"3722_CR3","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.ccell.2019.09.006","volume":"36","author":"R Grosser","year":"2019","unstructured":"Grosser R, Cherkassky L, Chintala N, Adusumilli PS. Combination immunotherapy with CAR T Cells and checkpoint blockade for the treatment of solid tumors. Cancer Cell. 2019;36:471\u201382.","journal-title":"Cancer Cell"},{"key":"3722_CR4","doi-asserted-by":"publisher","first-page":"3549","DOI":"10.1038\/s41467-020-17175-8","volume":"11","author":"M Hegde","year":"2020","unstructured":"Hegde M, et al. Tumor response and endogenous immune reactivity after administration of HER2 CAR T cells in a child with metastatic rhabdomyosarcoma. Nat Commun. 2020;11:3549.","journal-title":"Nat Commun"},{"key":"3722_CR5","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1016\/j.jaci.2020.07.025","volume":"146","author":"CW Freyer","year":"2020","unstructured":"Freyer CW, Porter DL. Cytokine release syndrome and neurotoxicity following CAR T-cell therapy for hematologic malignancies. J Allergy Clin Immunol. 2020;146:940\u20138.","journal-title":"J Allergy Clin Immunol"},{"key":"3722_CR6","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1158\/2326-6066.CIR-19-0404","volume":"7","author":"KV Woan","year":"2019","unstructured":"Woan KV, Miller JS. Harnessing natural killer cell antitumor immunity: from the bench to bedside. Cancer Immunol Res. 2019;7:1742\u20137.","journal-title":"Cancer Immunol Res"},{"key":"3722_CR7","doi-asserted-by":"publisher","DOI":"10.1002\/0471142735.im1109bs90","author":"C Watzl","year":"2010","unstructured":"Watzl C, Long EO. Signal transduction during activation and inhibition of natural killer cells. Curr Protoc Immunol. 2010. https:\/\/doi.org\/10.1002\/0471142735.im1109bs90.","journal-title":"Curr Protoc Immunol"},{"key":"3722_CR8","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1038\/s41573-022-00413-7","volume":"21","author":"NA Maskalenko","year":"2022","unstructured":"Maskalenko NA, Zhigarev D, Campbell KS. Harnessing natural killer cells for cancer immunotherapy: dispatching the first responders. Nat Rev Drug Discov. 2022;21:559\u201377.","journal-title":"Nat Rev Drug Discov"},{"key":"3722_CR9","doi-asserted-by":"publisher","first-page":"3051","DOI":"10.1182\/blood-2004-07-2974","volume":"105","author":"JS Miller","year":"2005","unstructured":"Miller JS, et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood. 2005;105:3051\u20137.","journal-title":"Blood"},{"key":"3722_CR10","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1002\/stem.2754","volume":"36","author":"H Zhu","year":"2018","unstructured":"Zhu H, Lai YS, Li Y, Blum RH, Kaufman DS. Concise review: human pluripotent stem cells to produce cell-based cancer immunotherapy. Stem Cells. 2018;36:134\u201345.","journal-title":"Stem Cells"},{"key":"3722_CR11","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1038\/leu.2017.226","volume":"32","author":"E Liu","year":"2018","unstructured":"Liu E, et al. Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity. Leukemia. 2018;32:520\u201331.","journal-title":"Leukemia"},{"key":"3722_CR12","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1056\/NEJMoa1910607","volume":"382","author":"E Liu","year":"2020","unstructured":"Liu E, et al. Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors. N Engl J Med. 2020;382:545\u201353.","journal-title":"N Engl J Med"},{"key":"3722_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02785-8","author":"D Marin","year":"2024","unstructured":"Marin D, et al. Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19(+) B cell tumors: a phase 1\/2 trial. Nat Med. 2024. https:\/\/doi.org\/10.1038\/s41591-023-02785-8.","journal-title":"Nat Med"},{"key":"3722_CR14","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1089\/15258160152509145","volume":"10","author":"T Tonn","year":"2001","unstructured":"Tonn T, Becker S, Esser R, Schwabe D, Seifried E. Cellular immunotherapy of malignancies using the clonal natural killer cell line NK-92. J Hematother Stem Cell Res. 2001;10:535\u201344.","journal-title":"J Hematother Stem Cell Res"},{"key":"3722_CR15","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1016\/j.jcyt.2013.06.017","volume":"15","author":"T Tonn","year":"2013","unstructured":"Tonn T, et al. Treatment of patients with advanced cancer with the natural killer cell line NK-92. Cytotherapy. 2013;15:1563\u201370.","journal-title":"Cytotherapy"},{"key":"3722_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2022.12.003","author":"H Klingemann","year":"2023","unstructured":"Klingemann H. The NK-92 cell line-30 years later: its impact on natural killer cell research and treatment of cancer. Cytotherapy. 2023. https:\/\/doi.org\/10.1016\/j.jcyt.2022.12.003.","journal-title":"Cytotherapy"},{"key":"3722_CR17","doi-asserted-by":"publisher","first-page":"89256","DOI":"10.18632\/oncotarget.19204","volume":"8","author":"BA Williams","year":"2017","unstructured":"Williams BA, et al. A phase I trial of NK-92 cells for refractory hematological malignancies relapsing after autologous hematopoietic cell transplantation shows safety and evidence of efficacy. Oncotarget. 2017;8:89256\u201368.","journal-title":"Oncotarget"},{"key":"3722_CR18","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1080\/14653240802301872","volume":"10","author":"S Arai","year":"2008","unstructured":"Arai S, et al. Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: a phase I trial. Cytotherapy. 2008;10:625\u201332.","journal-title":"Cytotherapy"},{"key":"3722_CR19","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1182\/blood.V100.4.1265.h81602001265_1265_1273","volume":"100","author":"C Uherek","year":"2002","unstructured":"Uherek C, et al. Retargeting of natural killer-cell cytolytic activity to ErbB2-expressing cancer cells results in efficient and selective tumor cell destruction. Blood. 2002;100:1265\u201373.","journal-title":"Blood"},{"key":"3722_CR20","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1111\/jcmm.12810","volume":"20","author":"A Romanski","year":"2016","unstructured":"Romanski A, et al. CD19-CAR engineered NK-92 cells are sufficient to overcome NK cell resistance in B-cell malignancies. J Cell Mol Med. 2016;20:1287\u201394.","journal-title":"J Cell Mol Med"},{"key":"3722_CR21","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000450","author":"KP Fabian","year":"2020","unstructured":"Fabian KP, et al. PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations. J Immunother Cancer. 2020. https:\/\/doi.org\/10.1136\/jitc-2019-000450.","journal-title":"J Immunother Cancer"},{"key":"3722_CR22","doi-asserted-by":"publisher","first-page":"533","DOI":"10.3389\/fimmu.2017.00533","volume":"8","author":"C Zhang","year":"2017","unstructured":"Zhang C, et al. Chimeric Antigen Receptor-Engineered NK-92 Cells: An Off-the-Shelf Cellular Therapeutic for Targeted Elimination of Cancer Cells and Induction of Protective Antitumor Immunity. Front Immunol. 2017;8:533.","journal-title":"Front Immunol"},{"key":"3722_CR23","doi-asserted-by":"publisher","first-page":"2683","DOI":"10.3389\/fimmu.2019.02683","volume":"10","author":"MC Burger","year":"2019","unstructured":"Burger MC, et al. CAR-Engineered NK Cells for the Treatment of Glioblastoma: Turning Innate Effectors Into Precision Tools for Cancer Immunotherapy. Front Immunol. 2019;10:2683.","journal-title":"Front Immunol"},{"key":"3722_CR24","doi-asserted-by":"crossref","unstructured":"Burger MC, et al. Intracranial injection of natural killer cells engineered with a HER2-targeted chimeric antigen receptor in patients with recurrent glioblastoma. Neuro Oncol. 2023;25:2058-71.","DOI":"10.1093\/neuonc\/noad087"},{"key":"3722_CR25","first-page":"1083","volume":"8","author":"X Tang","year":"2018","unstructured":"Tang X, et al. First-in-man clinical trial of CAR NK-92 cells: safety test of CD33-CAR NK-92 cells in patients with relapsed and refractory acute myeloid leukemia. Am J Cancer Res. 2018;8:1083\u20139.","journal-title":"Am J Cancer Res"},{"key":"3722_CR26","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s00262-017-2055-2","volume":"67","author":"P Nowakowska","year":"2018","unstructured":"Nowakowska P, et al. Clinical grade manufacturing of genetically modified, CAR-expressing NK-92 cells for the treatment of ErbB2-positive malignancies. Cancer Immunol Immunother. 2018;67:25\u201338.","journal-title":"Cancer Immunol Immunother"},{"key":"3722_CR27","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/s41571-019-0268-3","volume":"17","author":"DY Oh","year":"2020","unstructured":"Oh DY, Bang YJ. HER2-targeted therapies - a role beyond breast cancer. Nat Rev Clin Oncol. 2020;17:33\u201348.","journal-title":"Nat Rev Clin Oncol"},{"key":"3722_CR28","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1038\/mt.2014.219","volume":"23","author":"K Schonfeld","year":"2015","unstructured":"Sch\u00f6nfeld K et al. Selective inhibition of tumor growth by clonal NK cells expressing an ErbB2\/HER2-specific chimeric antigen receptor. Mol Ther. 2015;23:330-8.","journal-title":"Molecular therapy : the journal of the American Society of Gene Therapy"},{"key":"3722_CR29","doi-asserted-by":"crossref","unstructured":"Zhang C et al. ErbB2\/HER2-specific NK cells for targeted therapy of glioblastoma. J Natl Cancer Inst. 2016;108:djv375.","DOI":"10.1093\/jnci\/djv375"},{"key":"3722_CR30","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001334","author":"J Eitler","year":"2021","unstructured":"Eitler J, et al. Inability of granule polarization by NK cells defines tumor resistance and can be overcome by CAR or ADCC mediated targeting. J Immunother Cancer. 2021;9:e001334. https:\/\/doi.org\/10.1136\/jitc-2020-001334","journal-title":"J Immunother Cancer"},{"key":"3722_CR31","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-008155","volume":"12","author":"J Eitler","year":"2024","unstructured":"Eitler J, et al. CAR-mediated targeting of NK cells overcomes tumor immune escape caused by ICAM-1 downregulation. J Immunother Cancer. 2024;12:e008155.","journal-title":"J Immunother Cancer"},{"key":"3722_CR32","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1158\/2326-6066.CIR-18-0266","volume":"7","author":"DS Aldeghaither","year":"2019","unstructured":"Aldeghaither DS, et al. A Mechanism of Resistance to Antibody-Targeted Immune Attack. Cancer Immunol Res. 2019;7:230\u201343.","journal-title":"Cancer Immunol Res"},{"key":"3722_CR33","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","volume":"385","author":"DW Lee","year":"2015","unstructured":"Lee DW, et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet. 2015;385:517\u201328.","journal-title":"Lancet"},{"key":"3722_CR34","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002500","author":"M Bajor","year":"2022","unstructured":"Bajor M, et al. PD-L1 CAR effector cells induce self-amplifying cytotoxic effects against target cells. J Immunother Cancer. 2022. https:\/\/doi.org\/10.1136\/jitc-2021-002500.","journal-title":"J Immunother Cancer"},{"key":"3722_CR35","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1038\/mt.2013.185","volume":"21","author":"M Hegde","year":"2013","unstructured":"Hegde M, et al. Combinational targeting offsets antigen escape and enhances effector functions of adoptively transferred T cells in glioblastoma. Molecular therapy\u202f: the journal of the American Society of Gene Therapy. 2013;21:2087\u2013101.","journal-title":"Molecular therapy : the journal of the American Society of Gene Therapy"},{"key":"3722_CR36","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.54854","author":"Y Robbins","year":"2020","unstructured":"Robbins Y, et al. Tumor control via targeting PD-L1 with chimeric antigen receptor modified NK cells. Elife. 2020. https:\/\/doi.org\/10.7554\/eLife.54854.","journal-title":"Elife"},{"key":"3722_CR37","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-020-01027-5","volume":"14","author":"M Yi","year":"2021","unstructured":"Yi M, Niu M, Xu L, Luo S, Wu K. Regulation of PD-L1 expression in the tumor microenvironment. J Hematol Oncol. 2021;14:10.","journal-title":"J Hematol Oncol"},{"key":"3722_CR38","first-page":"652","volume":"8","author":"JH Gong","year":"1994","unstructured":"Gong JH, Maki G, Klingemann HG. Characterization of a human cell line (NK-92) with phenotypical and functional characteristics of activated natural killer cells. Leukemia. 1994;8:652\u20138.","journal-title":"Leukemia"},{"key":"3722_CR39","doi-asserted-by":"publisher","first-page":"3449","DOI":"10.4049\/jimmunol.181.5.3449","volume":"181","author":"HJ Pegram","year":"2008","unstructured":"Pegram HJ, Jackson JT, Smyth MJ, Kershaw MH, Darcy PK. Adoptive transfer of gene-modified primary NK cells can specifically inhibit tumor progression in vivo. J Immunol. 2008;181:3449\u201355.","journal-title":"J Immunol"},{"key":"3722_CR40","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1254821","author":"N Murali Shankar","year":"2023","unstructured":"Murali Shankar N, et al. Preclinical assessment of CAR-NK cell-mediated killing efficacy and pharmacokinetics in a rapid zebrafish xenograft model of metastatic breast cancer. Front Immunol. 2023. https:\/\/doi.org\/10.3389\/fimmu.2023.1254821.","journal-title":"Front Immunol"},{"key":"3722_CR41","doi-asserted-by":"publisher","DOI":"10.3390\/cells9040811","author":"P Oberoi","year":"2020","unstructured":"Oberoi P et al. Directed differentiation of mobilized hematopoietic stem and progenitor cells into functional NK cells with enhanced antitumor activity. Cells. 2020;9:811. https:\/\/doi.org\/10.3390\/cells9040811","journal-title":"Cells"},{"key":"3722_CR42","doi-asserted-by":"publisher","first-page":"10215","DOI":"10.18632\/oncotarget.7143","volume":"7","author":"S Chatterjee","year":"2016","unstructured":"Chatterjee S, et al. A humanized antibody for imaging immune checkpoint ligand PD-L1 expression in tumors. Oncotarget. 2016;7:10215\u201327.","journal-title":"Oncotarget"},{"key":"3722_CR43","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2020.1785608","volume":"9","author":"A Feldmann","year":"2020","unstructured":"Feldmann A, et al. Versatile chimeric antigen receptor platform for controllable and combinatorial T cell therapy. Oncoimmunology. 2020;9:1785608.","journal-title":"Oncoimmunology"},{"key":"3722_CR44","unstructured":"P. K. Ng et al., Systematic Functional Annotation of Somatic Mutations in Cancer. Cancer Cell 33, 450\u2013462 e410 (2018)."},{"key":"3722_CR45","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1007\/s00262-012-1212-x","volume":"61","author":"C Sahm","year":"2012","unstructured":"Sahm C, Sch\u00f6nfeld K, Wels WS. Expression of IL-15 in NK cells results in rapid enrichment and selective cytotoxicity of gene-modified effectors that carry a tumor-specific antigen receptor. Cancer Immunol Immunother. 2012;61:1451-61.","journal-title":"Cancer Immunol Immunother CII"},{"key":"3722_CR46","first-page":"341","volume":"42","author":"LR Loureiro","year":"2023","unstructured":"Loureiro LR, et al. Immunotheranostic target modules for imaging and navigation of UniCAR T-cells to strike FAP-expressing cells and the tumor microenvironment. J Exp Clin Cancer Res CR. 2023;42:341.","journal-title":"J Exp Clin Cancer Res CR"},{"key":"3722_CR47","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s13046-020-01572-4","volume":"39","author":"LR Loureiro","year":"2020","unstructured":"Loureiro LR, et al. Extended half-life target module for sustainable UniCAR T-cell treatment of STn-expressing cancers. Journal of experimental & clinical cancer research\u202f: CR. 2020;39:77.","journal-title":"Journal of experimental & clinical cancer research : CR"},{"key":"3722_CR48","doi-asserted-by":"publisher","first-page":"2320","DOI":"10.1016\/j.ymthe.2020.09.015","volume":"28","author":"J Wagner","year":"2020","unstructured":"Wagner J, Wickman E, DeRenzo C, Gottschalk S. CAR T Cell therapy for solid tumors: bright future or dark reality? Mol Ther. 2020;28:2320\u201339.","journal-title":"Mol Ther"},{"key":"3722_CR49","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/j.trecan.2024.05.007","volume":"10","author":"AD Posey Jr.","year":"2024","unstructured":"Posey AD Jr., Young RM, June CH. Future perspectives on engineered T cells for cancer. Trends Cancer. 2024;10:687\u201395.","journal-title":"Trends Cancer"},{"key":"3722_CR50","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2022.2127508","volume":"11","author":"MI Strecker","year":"2022","unstructured":"Strecker MI, et al. AAV-mediated gene transfer of a checkpoint inhibitor in combination with HER2-targeted CAR-NK cells as experimental therapy for glioblastoma. Oncoimmunology. 2022;11:2127508.","journal-title":"Oncoimmunology"},{"key":"3722_CR51","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.jcyt.2016.10.009","volume":"19","author":"S Oelsner","year":"2017","unstructured":"Oelsner S, et al. Continuously expanding CAR NK-92 cells display selective cytotoxicity against B-cell leukemia and lymphoma. Cytotherapy. 2017;19:235\u201349.","journal-title":"Cytotherapy"},{"key":"3722_CR52","doi-asserted-by":"crossref","unstructured":"S. Acharya et al., CD28 costimulation augments CAR signaling in NK cells via the LCK\/CD3Z\/ZAP70 signaling axis. Cancer discovery, (2024).","DOI":"10.1158\/2159-8290.27168675"},{"key":"3722_CR53","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-023-05778-2","author":"AM Tousley","year":"2023","unstructured":"Tousley AM, et al. Co-opting signalling molecules enables logic-gated control of CAR T cells. Nature. 2023. https:\/\/doi.org\/10.1038\/s41586-023-05778-2.","journal-title":"Nature"},{"key":"3722_CR54","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-18444-2","volume":"11","author":"HC Tseng","year":"2020","unstructured":"Tseng HC, et al. Efficacy of anti-CD147 chimeric antigen receptors targeting hepatocellular carcinoma. Nat Commun. 2020;11:4810.","journal-title":"Nat Commun"},{"key":"3722_CR55","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2015.1119354","volume":"5","author":"S Genssler","year":"2016","unstructured":"Genssler S, et al. Dual targeting of glioblastoma with chimeric antigen receptor-engineered natural killer cells overcomes heterogeneity of target antigen expression and enhances antitumor activity and survival. Oncoimmunology. 2016;5:e1119354.","journal-title":"Oncoimmunology"},{"key":"3722_CR56","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1186\/s12967-024-04990-6","volume":"22","author":"N Yang","year":"2024","unstructured":"Yang N, et al. CD19\/CD20 dual-targeted chimeric antigen receptor-engineered natural killer cells exhibit improved cytotoxicity against acute lymphoblastic leukemia. J Transl Med. 2024;22:274.","journal-title":"J Transl Med"},{"key":"3722_CR57","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1038\/s41591-022-02003-x","volume":"28","author":"Y Li","year":"2022","unstructured":"Li Y, et al. KIR-based inhibitory CARs overcome CAR-NK cell trogocytosis-mediated fratricide and tumor escape. Nat Med. 2022;28:2133\u201344.","journal-title":"Nat Med"}],"container-title":["Journal of Experimental &amp; Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13046-026-03722-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-026-03722-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-026-03722-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T07:02:04Z","timestamp":1779519724000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13046-026-03722-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,19]]},"references-count":57,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3722"],"URL":"https:\/\/doi.org\/10.1186\/s13046-026-03722-6","relation":{},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,19]]},"assertion":[{"value":"12 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The ascites fluid was collected for therapeutic purposes.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"TT, WSW, PO and MB are named as inventors on patents and patent applications in the field of cancer immunotherapy owned by their respective institutions. The other authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"127"}}